Get the Stockscreener App
60.01
1.66%
-1.01
After Hours:
60.01
Rhythm Pharmaceuticals Inc stock is traded at $60.01, with a volume of 350.27K.
It is down -1.66% in the last 24 hours and up +1.76% over the past month.
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.
See More
Previous Close:
$61.02
Open:
$60.55
24h Volume:
350.27K
Relative Volume:
0.65
Market Cap:
$3.69B
Revenue:
$112.53M
Net Income/Loss:
$-258.91M
P/E Ratio:
-13.86
EPS:
-4.33
Net Cash Flow:
$-124.42M
1W Performance:
+1.33%
1M Performance:
+1.76%
6M Performance:
+36.26%
1Y Performance:
+25.97%
1-Day Range:
$59.11
$60.84
1-Week Range:
$57.67
$62.14
52-Week Range:
$35.17
$68.58
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Name
Rhythm Pharmaceuticals Inc
Sector
Industry
Phone
857-264-4280
Address
222 BERKELEY STREET, BOSTON, MA
Compare RYTM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
60.01 | 3.69B | 112.53M | -258.91M | -124.42M | -4.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-02-25 | Initiated | Jefferies | Buy |
| Dec-20-24 | Initiated | Oppenheimer | Outperform |
| Oct-21-24 | Initiated | Guggenheim | Buy |
| Sep-18-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | JMP Securities | Mkt Outperform |
| May-08-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-01-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Aug-08-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-05-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-17-22 | Reiterated | Needham | Buy |
| Mar-02-22 | Resumed | Stifel | Buy |
| Feb-17-22 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-14-21 | Resumed | Goldman | Neutral |
| Aug-04-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Aug-04-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Nov-30-20 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-08-20 | Initiated | Goldman | Sell |
| Jul-12-19 | Upgrade | Stifel | Hold → Buy |
| Jul-08-19 | Initiated | Canaccord Genuity | Buy |
| Mar-13-19 | Initiated | Ladenburg Thalmann | Buy |
| Sep-07-18 | Resumed | Morgan Stanley | Overweight |
| Jun-25-18 | Reiterated | Needham | Buy |
| Jun-15-18 | Reiterated | Needham | Buy |
| Oct-30-17 | Initiated | BofA/Merrill | Buy |
| Oct-30-17 | Initiated | Needham | Buy |
View All
Rhythm Pharmaceuticals Inc Stock (RYTM) Latest News
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Sold by JGP Global Gestao de Recursos Ltda. - MarketBeat
Insider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CFO Sells 1,678 Shares of Stock - MarketBeat
David P. Meeker Sells 4,278 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock - MarketBeat
RYTMRhythm Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
RYTM (Rhythm Pharmaceuticals) Enterprise Value : $3,390.0 Mil (As of Feb. 05, 2025) - GuruFocus.com
Rhythm Pharmaceuticals to Present at Oppenheimer Annual Healthcare Life Sciences Conference in February - GlobeNewswire
An Analysis of Rhythm Pharmaceuticals Inc (RYTM)’s Potential Price Growth - Knox Daily
A History of Outperforming Analyst Forecasts and Beating the Odds: Rhythm Pharmaceuticals Inc (RYTM) - SETE News
Nisa Investment Advisors LLC Sells 64,955 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Rhythm Pharmaceuticals: Promising Weight Loss Breakthroughs and Strategic Advancements Justify Buy Rating - TipRanks
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Sold by Nisa Investment Advisors LLC - Defense World
Wall Street Analysts Think Rhythm Pharmaceuticals (RYTM) Could Surge 26.36%: Read This Before Placing a Bet - Yahoo Finance
How To Trade (RYTM) - Stock Traders Daily
Soligenix (NASDAQ:SNGX) & Rhythm Pharmaceuticals (NASDAQ:RYTM) Head to Head Contrast - Defense World
Rhythm Pharmaceuticals (RYTM) Soars 5.5%: Is Further Upside Left in the Stock? - MSN
Earnings call transcript: Rhythm Pharmaceuticals Q3 2024 sees growth - MSN
Rhythm Pharmaceuticals (NASDAQ:RYTM) Sees Large Volume IncreaseStill a Buy? - MarketBeat
Exploring High Growth Tech Stocks in January 2025 - Simply Wall St
Earnings call transcript: Rhythm Pharmaceuticals Q3 2024 sees growth By Investing.com - Investing.com Canada
Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price - Simply Wall St
JPMorgan Chase & Co. Sells 58,554 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Long Term Trading Analysis for (RYTM) - Stock Traders Daily
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives $68.09 Average Target Price from Analysts - Defense World
Head to Head Review: ABVC BioPharma (NASDAQ:ABVC) vs. Rhythm Pharmaceuticals (NASDAQ:RYTM) - Defense World
Rhythm gets FDA approval for Imcivree for toddlers - MSN
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Harbor Capital Advisors Inc. Sells 11,116 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Rhythm Pharmaceuticals (NASDAQ: RYTM) Reports Strong Growth in Revenue and Clinical Development Initiatives - Defense World
Rhythm Pharmaceuticals price target raised to $60 from $58 at BofA - MSN
Rhythm Pharmaceuticals, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year of 2024 - Marketscreener.com
Rhythm Pharmaceuticals Reports Growth and Expands Pipeline - TipRanks
Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones - The Manila Times
Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product - The Bakersfield Californian
Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter - GlobeNewswire
Rhythm Pharmaceuticals Delivers Record $130M Revenue in 2024, Q4 Sales Surge 26% - StockTitan
Principal Financial Group Inc. Has $1.71 Million Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Principal Financial Group Inc. Buys 23,054 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) Now Covered by Analysts at Jefferies Financial Group - Defense World
Jefferies starts Rhythm Pharmaceuticals with Buy on obesity potential - Yahoo Finance
Jefferies Financial Group Begins Coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) - MarketBeat
Where are the Opportunities in (RYTM) - Stock Traders Daily
Stifel Financial Corp Has $1.04 Million Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Rhythm Pharmaceuticals (NASDAQ:RYTM) Receives Market Outperform Rating from JMP Securities - Defense World
Rhythm Pharmaceuticals (NASDAQ:RYTM) Receives Buy Rating from HC Wainwright - Defense World
Rhythm Pharmaceuticals (NASDAQ:RYTM) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) Given "Market Outperform" Rating at JMP Securities - MarketBeat
Rhythm Pharmaceuticals Inc Stock (RYTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):